Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Evolocumab, a PCSK9 inhibitor, reduced risk for major adverse CV events in people with no history of heart attack or stroke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback